Clinical features of biochemical cholestasis in patients with recurrent hepatitis C after living-donor liver transplantation.
Recurrent hepatitis C after liver transplantation (HepC-LT) progresses faster than hepatitis C in non-transplant settings. Cholestasis has been suggested to be one characteristic of HepC-LT related to the rapid progression. We investigated the clinical features of biochemical cholestasis, which we defined as high serum concentrations of alkaline phosphatase and gamma-glutamyl transpeptidase, in patients with recurrent hepatitis C after living-donor liver transplantation. Eighty patients were diagnosed with post-transplant recurrent hepatitis C after exclusion of other aetiologies of cholestasis by liver biopsy and imaging. The clinical features of biochemical cholestasis in the patients with HepC-LT, including histological changes, the efficacy of interferon therapy and helper T-cell (Th) subsets in the peripheral blood, were analysed. Fifty-five of the 80 patients with HepC-LT (69%) had evidence of biochemical cholestasis. Progression of liver fibrosis to stage F3 or F4 was significantly accelerated in patients with biochemical cholestasis compared with patients without cholestasis. The biochemical cholestasis in patients with HepC-LT improved after interferon therapy in 22 of 39 patients (56%) who showed a virological response to the therapy, suggesting that hepatitis C virus (HCV) caused the biochemical cholestasis in these patients. Patients with biochemical cholestasis who had a biochemical response to interferon therapy showed an increased Th1 responses in peripheral blood. In conclusion, biochemical cholestasis is the characteristic feature of HepC-LT and is related to progression of liver fibrosis. An increased Th1 response is associated with cholestasis caused by HCV after liver transplantation.
Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. yueda@kuhp.kyoto-u.ac.jp
Y
Y
Ueda
Y
Y
Takada
H
H
Marusawa
H
H
Haga
T
T
Sato
Y
Y
Tanaka
H
H
Egawa
S
S
Uemoto
T
T
Chiba
D000469:Alkaline Phosphatase / Q000097:blood; D002779:Cholestasis / Q000473:pathology*; D006526:Hepatitis C / Q000150:complications*; D006651:Histocytochemistry; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D008099:Liver / Q000473:pathology; D008103:Liver Cirrhosis / Q000473:pathology; D016031:Liver Transplantation; D019520:Living Donors; D012008:Recurrence; D016176:T-Lymphocyte Subsets / Q000276:immunology; D016896:Treatment Outcome; D005723:gamma-Glutamyltransferase / Q000097:blood
D007372:Interferons; D005723:gamma-Glutamyltransferase; D000469:Alkaline Phosphatase